What it sells
We engineer proteins that control the operating system of biology.
Business model breakdown
Trigger: what makes them buy now?
Current methylation methods use sequence conversion and degradation that add noise; need sensitive early cancer/neurodegenerative detection and patient stratification.
Workflow: what inputs become what output?
EpiAmp is a methyl-preserving, conversion-free amplification chemistry; an end-to-end workflow gives single-day analysis for multiplexed assays at loci of interest.
Economics: what it saves and how it charges
UnverifiedLikely assay/tool sales and partnerships with biopharma; the site also mentions epigenetic editing therapeutics. Not stated.
Distribution: how it reaches customers
Partner-led and inbound: Partner with us / Contact us, sign up for updates, gated technical note.
Funding history and coverage
| Round date | Stage | Amount | Investors | Source |
|---|---|---|---|---|
| — | Y Combinator Summer 2021 | — | Y Combinator | ycombinator.com |
Profiles summarize public reporting and company websites. Business-model notes are MaxBC's reading of that material, not confirmed facts; unknowns are left blank rather than guessed. Updated 2026-10-12.